[go: up one dir, main page]

EE200200530A - Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid - Google Patents

Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid

Info

Publication number
EE200200530A
EE200200530A EEP200200530A EEP200200530A EE200200530A EE 200200530 A EE200200530 A EE 200200530A EE P200200530 A EEP200200530 A EE P200200530A EE P200200530 A EEP200200530 A EE P200200530A EE 200200530 A EE200200530 A EE 200200530A
Authority
EE
Estonia
Prior art keywords
pharmaceutical compositions
glycogen phosphorylase
phosphorylase inhibitors
inhibitors
glycogen
Prior art date
Application number
EEP200200530A
Other languages
English (en)
Estonian (et)
Inventor
Jay Hoover Dennis
Mysore Shanker Ravi
Thomas Friesen Dwayne
Alan Lorenz Douglas
Alan Schriver Nightingale James
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200200530A publication Critical patent/EE200200530A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
EEP200200530A 2000-03-16 2001-03-16 Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid EE200200530A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16
PCT/IB2001/000394 WO2001068055A1 (en) 2000-03-16 2001-03-16 Pharmaceutical compositions of glycogen phosphorylase inhibitors

Publications (1)

Publication Number Publication Date
EE200200530A true EE200200530A (et) 2004-04-15

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200530A EE200200530A (et) 2000-03-16 2001-03-16 Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid

Country Status (32)

Country Link
US (1) US20010053778A1 (xx)
EP (1) EP1263414A1 (xx)
JP (1) JP2003526654A (xx)
KR (1) KR20020081445A (xx)
CN (1) CN1418089A (xx)
AP (1) AP2002002621A0 (xx)
AR (1) AR027656A1 (xx)
AU (1) AU2001242669A1 (xx)
BG (1) BG107037A (xx)
BR (1) BR0109189A (xx)
CA (1) CA2403241A1 (xx)
CO (1) CO5280087A1 (xx)
CZ (1) CZ20022955A3 (xx)
EA (1) EA200200858A1 (xx)
EE (1) EE200200530A (xx)
HU (1) HUP0204583A2 (xx)
IL (1) IL151320A0 (xx)
IS (1) IS6508A (xx)
MA (1) MA26882A1 (xx)
MX (1) MXPA02009097A (xx)
NO (1) NO20024386L (xx)
OA (1) OA12232A (xx)
PA (1) PA8513601A1 (xx)
PE (1) PE20011184A1 (xx)
PL (1) PL360780A1 (xx)
SK (1) SK12622002A3 (xx)
SV (1) SV2002000343A (xx)
TN (1) TNSN01040A1 (xx)
TR (1) TR200202184T2 (xx)
WO (1) WO2001068055A1 (xx)
YU (1) YU67202A (xx)
ZA (1) ZA200207290B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0016555A (pt) * 1999-12-23 2002-09-17 Pfizer Prod Inc Composições farmacêuticas que proporcionam concentrações acrescidas de droga
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
JP2004529110A (ja) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
CN1523979A (zh) * 2001-06-22 2004-08-25 �Ʒ� 非晶形药物吸附物的药物组合物
BR0211028A (pt) * 2001-06-22 2004-06-15 Pfizer Prod Inc Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
EP1469832B2 (en) 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
PT1469833T (pt) 2002-02-01 2021-07-13 Bend Res Inc Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
BRPI0418330A (pt) * 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas de drogas de solubilidade baixa e poloxámeros
WO2005085245A1 (en) 2004-03-08 2005-09-15 Prosidion Limited Pyrrolopyridine-2-carboxylic acid hydrazides
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
CN107602710A (zh) 2012-08-24 2018-01-19 陶氏环球技术有限责任公司 新的具有高分子量和均匀性的酯化纤维素醚
CN109897004A (zh) 2012-09-11 2019-06-18 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
JP6843616B2 (ja) 2013-07-19 2021-03-17 シガ・テクノロジーズ・インコーポレーテッド アモルファステコビリマット調製
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832066B1 (en) * 1995-06-06 2001-09-12 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
AU2001242669A1 (en) 2001-09-24
AR027656A1 (es) 2003-04-09
PA8513601A1 (es) 2004-08-31
EA200200858A1 (ru) 2003-02-27
EP1263414A1 (en) 2002-12-11
BG107037A (bg) 2003-04-30
SK12622002A3 (sk) 2004-02-03
CZ20022955A3 (cs) 2003-09-17
MXPA02009097A (es) 2003-03-12
MA26882A1 (fr) 2004-12-20
CA2403241A1 (en) 2001-09-20
ZA200207290B (en) 2003-09-11
IL151320A0 (en) 2003-04-10
US20010053778A1 (en) 2001-12-20
HUP0204583A2 (hu) 2003-04-28
CO5280087A1 (es) 2003-05-30
KR20020081445A (ko) 2002-10-26
NO20024386L (no) 2002-11-13
IS6508A (is) 2002-08-16
TNSN01040A1 (fr) 2005-11-10
PL360780A1 (en) 2004-09-20
AP2002002621A0 (en) 2002-09-30
TR200202184T2 (tr) 2003-01-21
PE20011184A1 (es) 2001-11-15
YU67202A (sh) 2006-01-16
SV2002000343A (es) 2002-07-03
OA12232A (en) 2006-05-10
NO20024386D0 (no) 2002-09-13
WO2001068055A1 (en) 2001-09-20
CN1418089A (zh) 2003-05-14
BR0109189A (pt) 2003-05-27
JP2003526654A (ja) 2003-09-09

Similar Documents

Publication Publication Date Title
EE200200530A (et) Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
HU0101158D0 (en) Use of glycogen phosphorylase inhibitors
ITMI20010748A0 (it) Composizioni farmaceutiche
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
HUP0303146A3 (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors and pharmaceutical compositions containing them
PT1250343E (pt) Composicoes de antibioticos de azalida
EE200300052A (et) Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid
FI20011478L (fi) Farmaseuttinen koostumus
EE05020B1 (et) Glburiidi ravimkoostis
DK1458377T3 (da) Farmaceutiske sammensætninger indeholdende tegaserod
EE200300589A (et) Ravimkoostised
NO20026123L (no) Farmasöytiske sammensetninger
FI20022128A7 (fi) Farmaseuttinen koostumus
NO20031095D0 (no) Farmasöytiske sammensetninger
EP1328278A4 (en) GLUCOSAMINE ANALGESIC AND COMPOSITIONS
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
ITMI20000554A0 (it) Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono
IS6734A (is) Tríasólafleiður og lyfjasamsetningar sem innihalda þær
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
NO20042074L (no) Makrolider inneholdende farmasoytiske sammensetninger
EE200200689A (et) Ravimkoostised
PT1467737E (pt) Composicao farmaceutica orodispersivel de piribedil
IS6160A (is) Dífosfat salt af 4"-setinni-9-deoxó-9A-asa-9A-hómóerýtrómysín afleiðu og lyfjasamsetning þar af